{"id":"NCT00081770","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)","officialTitle":"Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-03","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2004-04-22","resultsPosted":"2009-10-30","lastUpdate":"2017-04-04"},"enrollment":4469,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"BIOLOGICAL","name":"PegIntron (peginterferon alfa-2b; SCH 54031)","otherNames":["PegIntron"]},{"type":"BIOLOGICAL","name":"PegIntron (peginterferon alfa-2b; SCH 54031)","otherNames":["PegIntron"]},{"type":"DRUG","name":"REBETOL (ribavirin; SCH 18908)","otherNames":["REBETOL [the Schering-Plough brand name for ribavirin]"]},{"type":"BIOLOGICAL","name":"PEGASYS (peginterferon alfa-2a)","otherNames":["PEGASYS"]},{"type":"DRUG","name":"COPEGUS (ribavirin)","otherNames":["COPEGUS [the Hoffman-La Roche brand name for ribavirin]"]}],"arms":[{"label":"PegIntron 1.5 ug/kg/wk plus REBETOL","type":"EXPERIMENTAL"},{"label":"PegIntron 1.0 ug/kg/wk plus REBETOL","type":"EXPERIMENTAL"},{"label":"PEGASYS 180 ug/wk Plus COPEGUS","type":"ACTIVE_COMPARATOR"}],"summary":"The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.","primaryOutcome":{"measure":"Sustained Virologic Response (SVR) Rate","timeFrame":"Assessed at the end of a 24-week post-treatment follow-up","effectByArm":[{"arm":"PegIntron 1.5 ug/kg/wk Plus REBETOL","deltaMin":39.8,"sd":null},{"arm":"PegIntron 1.0 ug/kg/wk Plus REBETOL","deltaMin":38,"sd":null},{"arm":"PEGASYS 180 ug/wk Plus COPEGUS","deltaMin":40.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.567"},{"comp":"OG000 vs OG001","p":"0.195"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19625712","21488082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":88,"n":1019},"commonTop":["FATIGUE","HEADACHE","INSOMNIA","NAUSEA","CHILLS"]}}